IPO Guru
Prasol Chemicals

Prasol Chemicals IPO Review

Prasol Chemicals IPO has been reviewed by 10 analysts, and the overall consensus is Apply — carrying a score of 83. Out of the 10 analysts who have covered this IPO, 7 recommend subscribing while 3 advise caution or avoidance — reflecting a broadly positive view from the analyst community.

The issue is priced in the band of ₹643-676 per share , with a minimum application size of 22 shares (minimum investment of approximately ₹14,872 at the upper band) . Subscription ran from 08 Sep 2026 to 10 Sep 2026. As of now, the grey market premium (GMP) for Prasol Chemicals IPO is quoting at ₹-13 (-1.92%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

General Review

Prasol Chemicals, incorporated in 1992 and based in Navi Mumbai, makes over 150 acetone-based, phosphorous-based and complex specialty chemicals for the paints, pharmaceutical, agrochemical and personal care industries, serving 1,618 customers across 69 countries. FY26 income was ₹1,237.85 crore with profit of ₹83.12 crore. Seven of the nine analysts said subscribe, one stayed neutral.

Listing Gains

The notes cluster the valuation between about 47 and 48.1 times FY26 earnings on post-issue capital. That is a full multiple in absolute terms, and analysts justify it on the pace of profit growth rather than on any discount to peers. The lone neutral rating reflects exactly that, pointing to a moderate listing.

Short Term Strategy

Profit nearly doubled in FY26, from ₹43.57 crore to ₹83.12 crore, with EBITDA rising to ₹139.32 crore on 22 percent revenue growth. One note describes the growth as genuinely accelerating. Fresh money repays ₹60 crore of borrowings, though most of the issue, ₹420 crore, is an offer for sale.

Long Term Strategy

Several analysts assign explicitly long-term ratings, citing three decades of experience, a broad product range, marquee customers including Alembic, Lubrizol and Clean Science, and low customer concentration at 23.68 percent from the top ten. The standing risk is operational: both plants have faced pollution control shutdowns, including a Mahad closure from October 2023 to May 2024.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Analyst Sentiment

Analytical Score

How it's calculated?
Apply
83 / 100

Recommend Subscribe

Based on 10 analyst reviews

7 / 10

Higher consensus indicates broader analyst agreement.

Analyst Review

Latest IPO Reviews

Frequently Asked Questions

Should I apply for Prasol Chemicals IPO?

Based on analyst coverage tracked on this page, the overall verdict for Prasol Chemicals IPO is Apply. Out of 10 analysts who have reviewed this IPO, 7 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 83 mean for Prasol Chemicals IPO?

The score of 83 is an aggregate of all analyst ratings tracked for Prasol Chemicals IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Scroll down to read individual analyst verdicts for more context.

What are the listing gain expectations for Prasol Chemicals IPO?

The notes cluster the valuation between about 47 and 48.1 times FY26 earnings on post-issue capital. That is a full multiple in absolute terms, and analysts justify it on the pace of profit growth rather than on any discount to peers. The lone neutral rating reflects exactly that, pointing to a moderate listing.

What is the price band and lot size of Prasol Chemicals IPO?

Prasol Chemicals IPO was priced at ₹643-676 per share. The minimum lot size is 22 shares, making the minimum investment approximately ₹14,872 at the upper end of the price band. Subscription ran from 08 Sep 2026 to 10 Sep 2026.

Explore Prasol Chemicals IPO Further

Track every stage of this IPO:

Advertisement
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.